NCT04898452 Intravenous Antibiotic Treatment at Home
| NCT ID | NCT04898452 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Helse Møre og Romsdal HF |
| Condition | Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2020-07-02 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2020-07-02 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to develop and evaluate a new model for across services interaction with the use of welfare technology and telemedicine. The model includes innovative and new routines for the exchange of patient information, quality systems and procedures between the municipality and the hospital. This model will first be tested for use in intravenous antibiotic therapy. The results of the study will be used to further develop the service. In the larger context, it is desirable to provide knowledge that is transferable to other diagnostic groups, treatment methods and geographical areas.
Eligibility Criteria
Inclusion criteria: * Main or bi-diagnosis during stay: A692 Borreliosis G00 - G009 Central nervous system inflammatory disorders I33 Endocarditis J86 Empyema D46.3 Spondylodiscitis M86 Osteomyelitis T84 Prosthesis / osteosynthesis infections M00.0-M00.9 Pyogen / septic arthritis J40-J47 Chronic diseases of the lower respiratory tract * Competent to give consent * The infection can not be treated with oral antibiotics in monotherapy * Selected IV antibiotics must be suitable for administration via selected pumps * The patient's condition is stable and does not require frequent observation by health care professionals * The patient is motivated and willing to participate in intravenous treatment in home hospitals * Must, after training, demonstrate mastery of practical procedures related to pump handling and any other procedures described in the patient's treatment plan * The home must be suitable for intravenous antibiotic treatment; access to refrigerators, hygienic conditions, social conditions * The patient must have a mobile phone and be able to handle the system for fast and secure communication with the Regional Response Center (RRO) Exclusion criteria: * consent not given
Contact & Investigator
Torstein Hole, md phd
STUDY DIRECTOR
Møre og Romsdal Hospital Trust
Frequently Asked Questions
Who can join the NCT04898452 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04898452 currently recruiting?
Yes, NCT04898452 is actively recruiting participants. Contact the research team at inger.stokke@helse-mr.no for enrollment information.
Where is the NCT04898452 trial being conducted?
This trial is being conducted at Kristiansund, Norway.
Who is sponsoring the NCT04898452 clinical trial?
NCT04898452 is sponsored by Helse Møre og Romsdal HF. The principal investigator is Torstein Hole, md phd at Møre og Romsdal Hospital Trust. The trial plans to enroll 50 participants.